The 45-day post-implantation results support use of a next-generation device in people with atrial fibrillation, but caution is advised until longer-term results are available.

A 91-year-old man with a history of bladder carcinoma and left total knee arthroplasty was evaluated because of left knee pain. A culture of synovial fluid showed no growth. A diagnosis was made.

Update at 3:41 a.m. Monday, Feb. 16, 2026: Episode 42 of the ongoing Halemaʻumaʻu Crater episodic summit eruption at Kīlauea volcano on the Big Island ended at 11:38 p.m. Sunday (Feb. 15) and the ...

Point-of-Care Ultrasound Devices Market OverviewThe point-of-care ultrasound (POCUS) devices market is witnessing steady expansion and is expected to grow at a compound annual growth rate of ...

Episode 42 ended after 9 hours and 48 minutes with both the north and south vents active for most of the eruption. The ...

Women are the first victims of air pollution produced by the Tunisian Chemical Group in Gabes. Today, women of the region are ...

Mechanisms, imaging-based patient selection, treatment gaps and opportunities, and future directions of embolization in sport-related and degenerative MSK pain.

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...

Phase III study will be "sufficient and pivotal for registration in the U.S." Kiniksa Pharmaceuticals ( KNSA 1.79%) ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript February 24, 2026 Kiniksa Pharmaceuticals, Ltd.